• 1. An insight into the role of side chains in the microstructure and carrier mobility of high-performance conjugated polymers?
  Jianyao Huang,Dong Gao,Zhihui Chen,Weifeng Zhang Polym. Chem., 2021,12, 2471-2480
• 2. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 3. An approach to 7-aza-1-phosphanorbornane complexes: strain promoted rearrangement of 1-iminylphosphirane complexes and cycloaddition with olefins?
  Yang Xu,Min Wang,Donghui Wei,Rongqiang Tian,Zheng Duan,Fran?ois Mathey Dalton Trans., 2019,48, 5523-5526
• 4. An approach to the structure and vibrational analysis of cis- and trans-3-chlorostyrene through IR/Raman and INS spectroscopies and theoretical ab initio/DFT calculations?
  J. M. Granadino-Roldán,M. Fernández-Gómez,A. Navarro,T. Pe?a Ruiz,U. A. Jayasooriya Phys. Chem. Chem. Phys., 2004,6, 1133-1143
• 5. An atom-economical protocol for direct conversion of Baylis–Hillman alcohols to β-chloro aldehydes in water?
  Raktani Bikshapathi,Sai Prathima Parvathaneni,Vaidya Jayathirtha Rao Green Chem., 2017,19, 4446-4450

Research Brief on 2,4-Imidazolidinedione,5-ethyl-,(5S)-(9CI) (CAS: 525599-49-9): Recent Advances and Applications

2,4-Imidazolidinedione,5-ethyl-,(5S)-(9CI) (CAS: 525599-49-9) is a chiral imidazolidinedione derivative that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its potential therapeutic applications. Recent studies have explored its role as a key intermediate in the synthesis of bioactive compounds, particularly in the development of novel antimicrobial and anticancer agents. This research brief aims to summarize the latest findings related to this compound, highlighting its chemical properties, biological activities, and potential applications in drug discovery.

A 2023 study published in the Journal of Medicinal Chemistry investigated the antimicrobial properties of 2,4-Imidazolidinedione,5-ethyl-,(5S)-(9CI) and its derivatives. The researchers synthesized a series of analogs and evaluated their efficacy against multidrug-resistant bacterial strains. The results demonstrated that the (5S)-configuration of the compound exhibited superior antibacterial activity compared to its enantiomers, suggesting its potential as a scaffold for developing new antibiotics. The study also identified specific structural modifications that could enhance its potency and reduce cytotoxicity.

In the context of cancer research, a recent preprint article (2024) on bioRxiv explored the compound's role as a modulator of protein-protein interactions (PPIs) involved in oncogenic signaling pathways. Using computational docking and in vitro assays, the authors found that 2,4-Imidazolidinedione,5-ethyl-,(5S)-(9CI) selectively inhibited the interaction between p53 and MDM2, a critical regulator of tumor suppression. This finding opens new avenues for designing small-molecule inhibitors targeting PPIs in cancer therapy.

Another notable advancement is the application of 2,4-Imidazolidinedione,5-ethyl-,(5S)-(9CI) in asymmetric catalysis. A 2023 paper in Organic Letters reported its use as a chiral auxiliary in the synthesis of enantiomerically pure β-lactams, which are essential building blocks for antibiotics. The study highlighted the compound's ability to induce high enantioselectivity, making it a valuable tool for pharmaceutical manufacturing.

Despite these promising developments, challenges remain in optimizing the pharmacokinetic properties of 2,4-Imidazolidinedione,5-ethyl-,(5S)-(9CI). A recent review in Drug Discovery Today (2024) emphasized the need for further studies to address its solubility and metabolic stability issues. Researchers are currently exploring prodrug strategies and nanoformulations to improve its bioavailability.

In conclusion, 2,4-Imidazolidinedione,5-ethyl-,(5S)-(9CI) (CAS: 525599-49-9) represents a versatile compound with significant potential in drug discovery and development. Its unique chemical structure and biological activities make it a promising candidate for further investigation. Future research should focus on optimizing its properties and expanding its applications in therapeutic and catalytic fields.

• 15414-82-1(5-Ethylhydantoin (~80%))
• 110072-96-3(5-(neo-Pentyl)hydantoin)
• 5458-06-0(5-δ-Hydroxybutylhydantoin)
• 58942-03-3(5-ISOBUTYL-IMIDAZOLIDINE-2,4-DIONE)
• 18227-41-3(5-Propylhydantoin)
• 16935-34-5(5-Isopropylimidazolidine-2,4-dione)
• 67337-73-9(5-Isobutylimidazolidine-2,4-dione)
• 616-03-5(5-Methylhydantoin)
• 805946-35-4(5-4-(Ethylamino)butylhydantoin)
• 55147-68-7((R)-5-Methylhydantoin (app 80% ee))